소아용 인플루엔자 예방 시장 : 시장 예측(2026-2032년)

The Paediatric Influenza Prevention Market is projected to grow by USD 2.27 billion at a CAGR of 10.14% by 2032.

Paediatric Influenza Prevention: Executive Overview

Paediatric influenza prevention encompasses vaccination, immunisation delivery, hygiene measures, surveillance, antiviral use when clinically indicated, and communication strategies designed to reduce infection and complications among children. The field is shaped by seasonal transmission, differences in national immunisation policy, unequal access to primary care, and the need to protect schools, households, and vulnerable contacts. Effective prevention combines clinical guidance with practical delivery systems that reach children reliably before and during influenza seasons.

Prevention Is Shifting Toward Integrated, Equitable Delivery

The prevention landscape is moving from isolated vaccination campaigns toward coordinated programmes linking paediatric care, schools, pharmacies, public-health agencies, and community organisations. Greater emphasis is being placed on timely seasonal planning, clear eligibility guidance, convenient administration settings, and targeted outreach to children with chronic conditions or other risk factors. Digital reminders, registry integration, community education, and stronger cold-chain and appointment workflows are also helping programmes address missed opportunities and improve continuity across seasons.

Artificial Intelligence Strengthens Planning, Surveillance, and Personalisation

Artificial intelligence can support paediatric influenza prevention by identifying patterns in surveillance data, improving demand and appointment planning, prioritising outreach, and assisting public-health teams in interpreting large volumes of clinical and epidemiological information. It may also help tailor reminders and educational content to different caregivers and communities. However, responsible use requires validated data, privacy safeguards, transparent decision processes, human oversight, and careful monitoring for bias-particularly where children, underserved populations, or incomplete health records are involved.

Regional Insights: Delivery Context Determines Prevention Outcomes

North America generally benefits from established immunisation infrastructure but continues to face challenges involving seasonal uptake, access disparities, and fragmented care pathways. Latin America's priorities include strengthening routine and seasonal delivery, cold-chain reliability, and outreach across urban, rural, and remote communities. Europe combines mature surveillance and health systems with substantial variation in national recommendations and delivery models. The Middle East requires approaches suited to diverse health systems, mobile populations, and differing access conditions, while Africa's priorities include supply reliability, primary-care capacity, surveillance, and community trust. Asia-Pacific presents a wide range of policy and infrastructure settings, making locally adapted schedules, school and community delivery, and equitable access especially important.

Group Insights: Policy Alignment and Access Shape Collective Action

ASEAN members face varied health-system capacity and benefit from coordinated surveillance, regional knowledge exchange, and adaptable outreach models. BRICS countries span highly diverse population sizes and delivery environments, making equity, domestic capacity, and interoperable surveillance important shared priorities. The European Union can leverage cross-border coordination, common technical learning, and national implementation flexibility. G7 members typically have strong research and delivery infrastructure but must address hesitancy, access gaps, and differences in coverage among vulnerable children. GCC countries can build on concentrated healthcare infrastructure while tailoring communication and services for expatriate and mobile populations. NATO members may benefit from resilience planning, continuity of essential paediatric services, and coordinated preparedness for health-system disruption.

Country Insights: National Systems Require Tailored Prevention Strategies

Australia can emphasise geographically equitable access and coordination across state and territory programmes. Brazil's priorities include reaching diverse communities, sustaining primary-care delivery, and addressing regional access differences. Canada must account for provincial and territorial variation while improving consistent access for remote and Indigenous communities. China can focus on broad preventive-care integration, surveillance, and caregiver communication across diverse local settings. France, Germany, Italy, and Spain can continue refining national and regional coordination, timely seasonal delivery, and protection of children with elevated clinical risk. India's priorities include scalable primary-care access, surveillance, affordability, and outreach across urban and rural populations. Japan and South Korea can build on strong health-system capabilities through timely seasonal planning and targeted caregiver engagement. Mexico can strengthen equitable delivery across regions and healthcare settings. Russia can focus on continuity of supply, surveillance, and access across geographically dispersed communities. The United Kingdom can use coordinated guidance, school-linked delivery where appropriate, and targeted support for underserved groups. The United States can continue addressing coverage variation, access barriers, caregiver confidence, and integration among paediatric, pharmacy, school, and public-health channels.

Actions for Leaders: Make Prevention Timely, Measurable, and Inclusive

Industry and health-system leaders should establish seasonal readiness plans that connect procurement, workforce capacity, appointment availability, communications, and surveillance. They should reduce friction through convenient delivery sites, reminder and recall systems, interoperable records, and clear clinical protocols. Programmes should segment outreach according to age, medical risk, geography, language, and access barriers rather than relying on broad messaging alone. Leaders should define measurable indicators such as timeliness, missed-opportunity rates, completion of recommended schedules, access by underserved group, adverse-event follow-up, and caregiver understanding. AI initiatives should begin with narrowly defined use cases, independent validation, strong governance, and routine equity audits.

Research Methodology: Evidence-Led Assessment of Prevention Systems

This executive summary uses a structured assessment of paediatric influenza prevention across interventions, delivery channels, policy environments, surveillance capabilities, access conditions, and technology adoption. Regional, group, and country comparisons are presented qualitatively, based on established public-health concepts and documented differences in healthcare organisation, population distribution, immunisation governance, and prevention infrastructure. The analysis separates observed system characteristics from potential applications of artificial intelligence and avoids unsupported claims about commercial scale, market performance, or future outcomes. Interpretation should be updated as national recommendations, epidemiological conditions, and delivery practices change.

Conclusion: Integrated Prevention Protects Children and Communities

Paediatric influenza prevention is most effective when vaccination and clinical guidance are supported by accessible services, dependable surveillance, trusted communication, and coordinated action across families, schools, providers, and public-health authorities. Regional and national differences make a single delivery model unsuitable, but common principles remain: act early, prioritise vulnerable children, reduce practical barriers, measure equity, and maintain strong governance. Leaders that combine operational readiness with evidence-based innovation-including carefully governed artificial intelligence-can strengthen prevention while preserving safety, trust, and accountability.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Paediatric Influenza Prevention Market, by Vaccine Type

• 7.1. Introduction
• 7.2. Inactivated Vaccine
  • 7.2.1. Split Virion
  • 7.2.2. Subunit
• 7.3. Live Attenuated Vaccine
• 7.4. Recombinant Vaccine

8. Paediatric Influenza Prevention Market, by Vaccine Technology

• 8.1. Introduction
• 8.2. Cell-Based
• 8.3. Egg-Based
• 8.4. Recombinant

9. Paediatric Influenza Prevention Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Intramuscular
• 9.3. Intranasal

10. Paediatric Influenza Prevention Market, by Age Group

• 10.1. Introduction
• 10.2. 2 To 8 Years
• 10.3. 6 To 23 Months
• 10.4. 9 To 17 Years

11. Paediatric Influenza Prevention Market, by Dosing Format

• 11.1. Introduction
• 11.2. Multi Dose Vial
  • 11.2.1. 10 Dose Vial
  • 11.2.2. 5 Dose Vial
• 11.3. Single Dose Syringe

12. Paediatric Influenza Prevention Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Private Sector
  • 12.2.1. Hospital Pharmacies
  • 12.2.2. Retail Pharmacies
• 12.3. Public Sector

13. Paediatric Influenza Prevention Market, by End User

• 13.1. Introduction
• 13.2. Clinics
  • 13.2.1. Primary Care Clinics
  • 13.2.2. Specialty Clinics
• 13.3. Hospitals

14. Paediatric Influenza Prevention Market, by Region

• 14.1. Introduction
• 14.2. Asia-Pacific
• 14.3. North America
• 14.4. Latin America
• 14.5. Europe
• 14.6. Middle East
• 14.7. Africa

15. Paediatric Influenza Prevention Market, by Group

• 15.1. Introduction
• 15.2. ASEAN
• 15.3. GCC
• 15.4. European Union
• 15.5. BRICS
• 15.6. G7
• 15.7. NATO

16. Paediatric Influenza Prevention Market, by Country

• 16.1. Introduction
• 16.2. United States
• 16.3. Canada
• 16.4. Mexico
• 16.5. Brazil
• 16.6. United Kingdom
• 16.7. Germany
• 16.8. France
• 16.9. Russia
• 16.10. Italy
• 16.11. Spain
• 16.12. China
• 16.13. India
• 16.14. Japan
• 16.15. Australia
• 16.16. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. Market Concentration Analysis, 2025
  • 17.2.1. Concentration Ratio (CR)
  • 17.2.2. Herfindahl Hirschman Index (HHI)
• 17.3. Recent Developments & Impact Analysis, 2025
• 17.4. Product Portfolio Analysis, 2025
• 17.5. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Laboratories
• 18.2. Altimmune, Inc.
• 18.3. AstraZeneca plc
• 18.4. Bharat Biotech International Ltd.
• 18.5. BioCryst Pharmaceuticals, Inc.
• 18.6. China National Pharmaceutical Group Co., Ltd.
• 18.7. CSL Limited
• 18.8. Daiichi Sankyo Company, Limited
• 18.9. FluGen, Inc.
• 18.10. GlaxoSmithKline plc
• 18.11. Hualan Biological Engineering Inc.
• 18.12. Johnson & Johnson
• 18.13. Merck & Co., Inc.
• 18.14. Mitsubishi Tanabe Pharma Corporation
• 18.15. Novavax, Inc.
• 18.16. Pfizer Inc.
• 18.17. Sanofi S.A.
• 18.18. Seqirus
• 18.19. Serum Institute of India Pvt. Ltd.
• 18.20. Sinovac Biotech Ltd.
• 18.21. SK Bioscience Co., Ltd.
• 18.22. Takeda Pharmaceutical Company Limited
• 18.23. Teva Pharmaceutical Industries Ltd.
• 18.24. Vaxart, Inc.
• 18.25. Viatris Inc.

19. Key Experts